Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nasal challenge with allergen leads to maxillary sinus inflammation

Published byMartin Wade Modified over 7 years ago

Similar presentations

Presentation on theme: "Nasal challenge with allergen leads to maxillary sinus inflammation"— Presentation transcript:

1 Nasal challenge with allergen leads to maxillary sinus inflammation
Fuad M. Baroody, MD, Samantha M. Mucha, MD, Marcy deTineo, BSN, Robert M. Naclerio, MD  Journal of Allergy and Clinical Immunology  Volume 121, Issue 5, Pages e7 (May 2008) DOI: /j.jaci Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Challenge protocol for subjects, depicting time points of catheter insertion, sneezing and nasal symptom (Sxs) recording, and nasal and sinus lavage. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Median sneezes and rhinorrhea and congestion scores for allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, number of sneezes; B, rhinorrhea score; C, congestion score. The protocol is on the x-axis. Pre, Baseline prewash; Dil, diluent for the allergen extract, A, allergen challenge. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Median levels of mediators in the nasal cavity after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, albumin; B, histamine; C, ECP. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Median number of eosinophils in the nasal cavity and maxillary sinus after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, nasal cavity; B, maxillary sinus. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Median levels of mediators in the maxillary sinus after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, albumin; B, histamine; C, ECP. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P ≤ .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig 6 Percentage of eosinophils in blood, the maxillary sinus, and the nasal cavity after allergen challenge depicted as individual values with median bars. The maxillary sinus and nasal cavity data are presented as the median value for the peak LPR percentage of eosinophils for each subject. ∗P ≤ .01 versus blood value. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Nasal challenge with allergen leads to maxillary sinus inflammation"

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Chronic rhinosinusitis: Potential new use for topical sulfasalazine
Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?

Similar presentations

Ads by Google